Medicare Enrolled
Dr. Rami Haddad, MD
Hematology & Oncology · Oak Lawn, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Haddad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haddad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Haddad
Dr. Rami Haddad is a hematology & oncology specialist in Oak Lawn, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Haddad performed 87,289 Medicare services across 1,835 unique beneficiaries.
Between the years covered by Open Payments, Dr. Haddad received a total of $49,628 from 94 pharmaceutical and/or device companies across 1343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Haddad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in IL
$49,628 industry payments
Medicare Practice Summary
Medicare Utilization ↗87,289
Medicare services
Top 12% in IL for hematology & oncology
1,835
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,594 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
20,760 | $0 | $6 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
19,500 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 13,000 | $43 | $147 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,500 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 9,540 | $18 | $71 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
6,860 | $2 | $21 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,240 | $0 | $2 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
829 | $66 | $270 |
| Anti-nausea injection (Aloxi/palonosetron) | 810 | $1 | $122 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
687 | $99 | $400 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
389 | $109 | $686 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
372 | $11 | $93 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
363 | $66 | $270 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
310 | $1 | $6 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
290 | $13 | $105 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
258 | $2 | $300 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
173 | $24 | $152 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
152 | $24 | $156 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
118 | $60 | $205 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
107 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
106 | $53 | $304 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
99 | $6 | $462 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
97 | $54 | $334 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
86 | $1 | $19 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 71 | $404 | $638 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
68 | $1,299 | $4,120 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $135 | $530 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
50 | $0 | $3 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
49 | $143 | $750 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
44 | $94 | $467 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
39 | $256 | $758 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
37 | $2 | $19 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
36 | $28 | $141 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
36 | $114 | $620 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
35 | $26 | $249 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
34 | $106 | $510 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
32 | $21 | $90 |
| New patient office visit, complex (60-74 min) | 27 | $170 | $760 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
15 | $89 | $378 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
14 | $146 | $523 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.3% high complexity
74.2% medium
2.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$49,628
Total received (2018-2024)
Avg $7,090/year across 7 years
Top 14% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
94
Companies
1,343
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$22,523 (45.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,899 (40.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,742 (11.6%)
Other
Charitable contributions, space rental, and other categories
$1,464 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,828
2023
$9,239
2022
$8,283
2021
$10,021
2020
$2,855
2019
$4,298
2018
$10,104
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$871
Novartis Pharmaceuticals Corporation
$429
Janssen Biotech, Inc.
$301
PFIZER INC.
$289
Merck Sharp & Dohme LLC
$272
E.R. Squibb & Sons, L.L.C.
$232
ABBVIE INC.
$219
Takeda Pharmaceuticals U.S.A., Inc.
$194
Regeneron Healthcare Solutions, Inc.
$191
Alexion Pharmaceuticals, Inc.
$185
Daiichi Sankyo Inc.
$142
Tempus AI, Inc
$129
GlaxoSmithKline, LLC.
$125
Incyte Corporation
$116
Celgene Corporation
$89
Astellas Pharma US Inc
$72
EMD Serono, Inc.
$66
Gilead Sciences, Inc.
$66
Blueprint Medicines Corporation
$55
Lilly USA, LLC
$52
Sumitomo Pharma America, Inc.
$47
TAIHO ONCOLOGY, INC.
$45
Deciphera Pharmaceuticals Inc.
$45
Bayer Healthcare Pharmaceuticals Inc.
$44
BeiGene USA, Inc.
$44
GENZYME CORPORATION
$44
Eisai Inc.
$40
Genentech USA, Inc.
$39
SOBI, INC
$39
ARRAY BIOPHARMA INC
$35
Aveo Pharmaceuticals, Inc.
$34
Kite Pharma, Inc.
$33
TerSera Therapeutics LLC
$28
Mirati Therapeutics, Inc.
$27
Apellis Pharmaceuticals, Inc.
$26
PROGENICS PHARMACEUTICALS, INC.
$26
Pharmacosmos Therapeutics Inc.
$25
Karyopharm Therapeutics Inc.
$22
MorphoSys, US Inc.
$21
SERVIER PHARMACEUTICALS LLC
$20
PUMA BIOTECHNOLOGY, INC.
$19
Agios Pharmaceuticals, Inc.
$15
Janssen Pharmaceuticals, Inc
$15
Top 3 companies account for 33.2% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$9,515
TESARO, Inc.
$4,368
Regeneron Healthcare Solutions, Inc.
$3,035
Amgen Inc.
$2,883
PFIZER INC.
$2,625
Novartis Pharmaceuticals Corporation
$2,507
Exelixis Inc.
$2,357
Puma Biotechnology, Inc.
$2,019
E.R. Squibb & Sons, L.L.C.
$1,588
Rigel Pharmaceuticals, Inc.
$1,499
Merck Sharp & Dohme Corporation
$1,294
Incyte Corporation
$1,228
Seattle Genetics, Inc.
$1,196
Bayer HealthCare Pharmaceuticals Inc.
$1,160
Janssen Biotech, Inc.
$1,112
Lilly USA, LLC
$1,085
Genentech USA, Inc.
$837
Merck Sharp & Dohme LLC
$674
BeiGene, Ltd.
$525
Takeda Pharmaceuticals U.S.A., Inc.
$467
Pharmacyclics LLC, An AbbVie Company
$413
Gilead Sciences, Inc.
$405
Celgene Corporation
$393
GENZYME CORPORATION
$373
Daiichi Sankyo Inc.
$355
Seagen Inc.
$334
Astellas Pharma US Inc
$327
Eisai Inc.
$297
GlaxoSmithKline, LLC.
$288
ABBVIE INC.
$285
Janssen Pharmaceuticals, Inc
$284
Alexion Pharmaceuticals, Inc.
$275
EMD Serono, Inc.
$258
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Global Blood Therapeutics, Inc.
$187
ARRAY BIOPHARMA INC
$152
Blueprint Medicines Corporation
$141
Boehringer Ingelheim Pharmaceuticals, Inc.
$130
Tempus AI, Inc
$129
MorphoSys, US Inc.
$117
Ipsen Biopharmaceuticals, Inc
$104
G1 Therapeutics, Inc.
$101
Jazz Pharmaceuticals Inc.
$98
Bayer Healthcare Pharmaceuticals Inc.
$89
AMAG Pharmaceuticals, Inc.
$88
JAZZ PHARMACEUTICALS INC.
$82
Kite Pharma, Inc.
$80
BeiGene USA, Inc.
$78
Pharmacyclics LLC, an AbbVie Company
$78
Clovis Oncology, Inc.
$72
EISAI INC.
$70
SANOFI-AVENTIS U.S. LLC
$65
Sumitomo Pharma America, Inc.
$61
Aurobindo Pharma USA, Inc.
$56
PUMA BIOTECHNOLOGY, INC.
$56
SERVIER PHARMACEUTICALS LLC
$53
Verastem, Inc.
$50
Pharmacosmos Therapeutics Inc.
$47
Karyopharm Therapeutics Inc.
$47
TAIHO ONCOLOGY, INC.
$45
Deciphera Pharmaceuticals Inc.
$45
RECORDATI_RARE_DISEASES_INC.
$45
Kyowa Kirin, Inc.
$45
Mirati Therapeutics, Inc.
$42
AbbVie, Inc.
$41
Genentech, Inc.
$40
SOBI, INC
$39
Myovant Sciences Inc.
$36
Aveo Pharmaceuticals, Inc.
$34
TOLMAR Pharmaceuticals, Inc.
$33
Sun Pharmaceutical Industries Inc.
$33
TerSera Therapeutics LLC
$28
Helsinn Therapeutics (U.S.), Inc.
$27
Apellis Pharmaceuticals, Inc.
$26
PROGENICS PHARMACEUTICALS, INC.
$26
Foundation Medicine, Inc.
$24
Stemline Therapeutics Inc.
$22
Advanced Accelerator Applications
$18
GE HealthCare
$18
AbbVie Inc.
$18
Teva Pharmaceuticals USA, Inc.
$17
ADC Therapeutics America, Inc.
$17
Fortovia Therapeutics, Inc.
$16
Lexicon Pharmaceuticals, Inc.
$16
Myriad Genetic Laboratories, Inc.
$16
Acrotech Biopharma LLC
$16
Immunomedics, Inc.
$16
Agios Pharmaceuticals, Inc.
$15
Novo Nordisk Inc
$14
Secura Bio, Inc.
$14
Medtronic USA, Inc.
$13
Dova Pharmaceuticals
$13
EUSA Pharma (US) LLC
$11
Acceleron Pharma, Inc.
$11
Top 3 companies account for 34.1% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · ASPARLAS · AYVAKIT · Abraxane · Adcetris · Alecensa · Aliqopa · Avastin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Erivedge · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Farydak · GAZYVA · GILOTRIF · HEMADY · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MOVANTIK · MVASI · Marqibo · NERLYNX · NINLARO · Nerlynx · Neulasta · Novoeight · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PREZCOBIX · PROMACTA · PYLARIFY · Padcev · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SUTENT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · VYXEOS · Vanflyta · Venclexta · Vitrakvi · Vyloy · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · YONSA · YONSA (abiraterone acetate) · Yescarta · ZEJULA · ZEPZELCA · Zevalin · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (45%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
345
Per 100K population
6.7
County median income
$81,797
Nearest hospital
ADVOCATE CHRIST HOSPITAL & MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Haddad is a mixed practice specialist, with above-average Medicare volume (top 12% in IL), with consulting-driven industry engagement in the top 14% of IL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Haddad experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Haddad performed 20,760 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Haddad receive payments from pharmaceutical companies?
Yes. Dr. Haddad received a total of $49,628 from 94 companies across 1,343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haddad's costs compare to other hematology & oncology specialists in Oak Lawn?
Dr. Haddad's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haddad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Oak Lawn
Browse hematology & oncology specialists in Oak Lawn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology